Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial - Concepedia

Concepedia

Publication | Closed Access

Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial

138

Citations

20

References

2006

Year

Stephen Chia, Mark Clemons, L Abdel Kader Martin, A. Rodgers, Karen A. Gelmon, Gregory R. Pond, Lawrence Panasci

Journal of Clinical Oncology

Abstract

The combination of PLD and trastuzumab is a well tolerated and active regimen in HER-2-positive MBC. Cardiotoxicity was observed, but limited to asymptomatic declines in LVEF. Further evaluation of this combination is warranted.

References

	Year	Citations

Page 1